一、监事会会议召开情况 证券代码：300326 证券简称：凯利泰 公告编号：2024-025 上海凯利泰医疗科技股份有限公司 第五届监事会第十五次决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 表决结果：本议案以 3 票同意、0 票反对、0 票弃权获得通过。 《上海凯利泰医疗科技股份有限公司 2024 年第一季度报告》请详见中国证 监会指定的创业板信息披露网站。 1 三、备查文件 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 20 日以邮件方式向公司各监事发出关于召开第五届监事会第十五次会议的通知，并 于 2024 年 4 月 22 日 14 时在公司会议室以现场结合通讯方式召开。本次监事会 会议应出席的监事 3 名，实际出席会议的监事 3 名，其中周志强以通讯表决方式 出席会议。会议由周志强先生主持，公司董事会秘书列席本次会议。本次会议的 召集、召开符合《中华人民共和国公司法》和《上海凯利泰医疗科技股份有限公 司章程》的规定。 二、监事会会议审议情况 审议通过了《关于公司 2024 年第一季度报告的议案》 经审核，监事 ...

审议通过了《关于公司 2024 年第一季度报告的议案》 证券代码：300326 证券简称：凯利泰 公告编号：2024-023 上海凯利泰医疗科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 19 日以邮件方式向公司各董事发出关于召开第五届董事会第十五次会议的通知，并 于 2024 年 4 月 22 日 14 时 30 分在公司会议室以现场结合通讯方式召开。本次董 事会会议应出席的董事 7 名，实际出席会议的董事 7 名，其中王正民、王冲、郑 卫茂、戴雪光、鲁旭波以通讯表决方式出席会议。会议由董事长袁征先生主持， 公司部分监事和高级管理人员列席会议。本次会议的召集、召开符合《中华人民 共和国公司法》和《上海凯利泰医疗科技股份有限公司章程》的规定。 二、董事会会议审议情况 1、《上海凯利泰医疗科技股份有限公司第五届董事会第十五次会议决议》； 2、《上海凯利泰医疗科技股份有限公司第五届董事会审计委员会第八次会议 决议》 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 246.21 million, a decrease of 16.37% compared to CNY 294.40 million in the same period last year[6]. - Net profit attributable to shareholders was CNY 10.88 million, down 85.48% from CNY 74.90 million year-on-year[6]. - The basic earnings per share decreased to CNY 0.0152, down 85.48% from CNY 0.1045 in the same period last year[6]. - Net profit for Q1 2024 was CNY 16.55 million, a decline of 78.0% from CNY 75.08 million in Q1 2023[29]. - The company reported a significant drop in investment income, recording a loss of CNY 2.45 million compared to a gain of CNY 29.19 million in the same period last year[29]. Cash Flow - The net cash flow from operating activities was negative CNY 19.50 million, a decline of 125.48% compared to CNY 76.51 million in the previous year[6]. - The net cash flow from operating activities for the current period is -19.50 million, a decrease of 9.60 million or 125.48% compared to the same period last year, primarily due to reduced revenue in the orthopedic manufacturing and trading segments[19]. - The net cash flow from investment activities is -24.39 million, a decrease of 17.28 million or 243.03% year-over-year, attributed to increased investment payments and net cash outflow from bank wealth management[20]. - The net cash flow from financing activities is 0.93 million, an increase of 6.05 million or 118.21% compared to the previous year, mainly due to an increase in net bank borrowings and reduced interest expenses[20]. - The company’s cash flow from operating activities showed a decline, reflecting challenges in revenue generation[28]. - The net cash flow from operating activities was -19,497,653.07 yuan, a significant decrease compared to 76,514,802.08 yuan in the previous period, indicating a decline in operational performance[31]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3.35 billion, a slight decrease of 0.12% from CNY 3.35 billion at the end of the previous year[6]. - The total assets as of the end of Q1 2024 were CNY 3.35 billion, slightly down from CNY 3.35 billion at the end of Q4 2023[26]. - Total liabilities decreased to CNY 383.62 million from CNY 405.35 million in the previous quarter[26]. Operational Challenges - The implementation of the national volume-based procurement policy significantly impacted the sales prices of orthopedic products, leading to a substantial decline in revenue and profit[9]. - The company expects continued challenges in the orthopedic segment due to the ongoing effects of the procurement policy[9]. - The company reported a significant decrease in financial expenses due to lower financing costs compared to the previous year[19]. - Other income decreased due to a reduction in government subsidies recognized during the reporting period[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 50,022[22]. - The largest shareholder, Yongjin Investment Holdings, holds 6.99% of the shares, totaling 50,100,000 shares[22]. Investment and Expenditures - The company's investment in non-current assets increased by CNY 1.40 million, reflecting ongoing investments in medical technology[14]. - Research and development expenses increased to CNY 14.98 million, up from CNY 13.02 million in the previous year, indicating a focus on innovation[28]. - The cash paid for purchasing fixed assets and intangible assets was 12,919,004.65 yuan, up from 7,757,749.26 yuan, indicating increased capital expenditures[33]. - The company paid 25,000,000.00 yuan to repay debts, a decrease from 69,129,870.12 yuan in the previous period, suggesting a reduction in debt repayment obligations[33]. Liquidity - Cash and cash equivalents decreased by CNY 25.38 million, primarily due to the use of funds for purchasing bank wealth management products[12]. - The company's cash and cash equivalents decreased from 620.44 million to 366.59 million, reflecting a significant reduction in liquidity[24]. - The total cash and cash equivalents at the end of the period decreased to 361,137,590.27 yuan from 654,769,877.61 yuan, reflecting a significant reduction in liquidity[33]. - The impact of exchange rate changes on cash and cash equivalents was 186,019.31 yuan, contrasting with -2,103,212.22 yuan in the previous period, indicating a positive effect from currency fluctuations[33].

2023年度监事会工作报告 2023年，上海凯利泰医疗科技股份有限公司（以下简称"公司"） 监事会严格按照《公司法》、《公司章程》、《深圳证券交易所上市 公司自律监管指引第2号-创业板上市公司规范运作指引》、《监事会 议事规则》等有关法律法规及公司内控制度的要求，从切实维护公司 利益和广大股东权益出发，认真履行了监督职责。监事会成员通过列 席历次董事会和股东大会会议，对重大决策事项进行监督，对公司财 务状况及董事、高管人员履职情况进行监督，确保公司能够规范、有 序的运作。现将监事会在报告期内的工作情况报告如下： 一、2023年度公司监事会工作情况 《关于修改公司〈关联交易决策制度〉的议案》、《关于会计政策变更 的议案》、《关于修改公司〈对外担保管理制度〉的议案》、《关于计提 江苏艾迪尔医疗科技股份有限公司商誉减值准备的议案》； 2、2023 年 4 月 24 日，公司第五届监事会第八次会议在公司会 议室以现场结合通讯方式召开，会议审议并通过了《关于公司 2023 年第一季度报告的议案》； 3、2023 年 8 月 24 日，公司第五届监事会第九次会议在公司会 议室以现场结合通讯方式召开，审议通过了《关于公司 ...

| 汇总 | | --- | | 年度非经营性资金占用及其他关联资金往来情况汇/ | 上海凯利泰医疗科技股份有 | 实际控制人及其附属 到单位：上海凯利泰医疗科技股份有 非经营性 资金占用 小计 股股东、 | 资金占用方名 | 用方与上市公司 的关联关系 | 市公司核算的 会计科目 | 023年期初占 | 023年度占用累计发生金 额（不含利息） | 2023年度占用资金的 | 2023年度偿还 计发生金额 | 2023年期末占 | 占用形成原 | 单位:万元 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 实际控制人及其附属 小计 小计 也关联方及其附属企 控股股东、 | | | | | | | | | | | | 总计 其他关联 资金在来 | 金往来方名 | 来方与上市公司 的关联关系 | 市公司核算的 会计科目 | 23年期初占用 资金余额 | 23年度占用累计发生金 额（不含利息） | 023年度占用资金 利息（如有） | 023年度偿还 计发生金额 | 2023年期末占 资金余额 | 主来形成原 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-016 上海凯利泰医疗科技股份有限公司 关于向合营公司提供财务资助暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1、上海凯利泰医疗科技股份有限公司(以下简称"公司")拟向合营公司上海意 久泰医疗科技有限公司(以下简称"上海意久泰")提供借款人民币 7,140,000 元， 借款年利率为 4.20%，借款期限为五年，自上海意久泰收到首笔借款之日起起算， 上海意久泰应于借款到期日之时向公司支付借款的全部本金及利息。 2、上海意久泰其他股东 Tecres S.p.A.同意按持股比例等比例向其提供借款 人民币 6,860,000 元，借款年利率为 4.20%，借款期限为五年，自上海意久泰收 到首笔借款之日起起算，上海意久泰应于借款到期日之时向 Tecres S.p.A.支付借 款的全部本金及利息。 3、本次财务资助暨关联交易事项已经公司第五届董事会第十四次会议和第 五届监事会第十四次会议审议通过，需提交公司股东大会审议。 4、本次财务资助暨关联交易被资助对象为公司的合营公 ...

大华会计师事务所（特殊普通合伙）（以下简称"大华所"）成立于 1985 年，2012 年 2 月由大华会计师事务所有限公司转制为特殊普通合伙。注册地址 在北京市海淀区西四环中路 16 号院 7 号楼 1101，首席合伙人为梁春。截至 2023 年 12 月 31 日合伙人 270 人，注册会计师 1471 人（其中：签署过证券服务业务 审计报告的注册会计师1141人）。大华所在国内重要城市设立了30家分支机构。 2022 年度业务总收入 33.27 亿元、审计业务收入 30.74 亿元、证券业务收入 13.89 亿元。 （二）聘任会计师事务所履行的程序 公司于 2023 年 4 月 20 日召开第五届董事会第七次会议，审议通过了《关于 公司续聘财务审计机构的议案》，后该议案于 2023 年 5 月 24 日经 2023 年年度 股东大会审议通过。公司独立童事对上述议案发表了事前认可和同意的独立意见。 二、审计委员会对会计师事务所监督情况 上海凯利泰医疗科技股份有限公司董事会审计委员会 对会计师事务所 2023 年度履行监督职责情况报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 治理准 ...

上海凯利泰医疗科技股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2024]0011009727 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 上海凯利泰医疗科技股份有限公司 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 控股股东及其他关联方 资金占用情况的专项说明 大华核字[2024] 0011009727号 上海凯利泰医疗科技股份有限公司全体股东： 根据中国证券监督管理委员会发布的《上市公司监管指引第 8 号 ——上市公司资金往来、对外担保的监管要求》（证监会公告[2022]26 号）和深圳证券交易所《深圳证券交易所创业板上市公司自律监管指 南第 1 号——业务办理（2023 年 2 月修订）》的规定，就凯利泰编制 的 2023 年度非经营性资金占用及其他关 ...

上海凯利泰医疗科技股份有限公司 审计报告 大华审字[2024]0011002303 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） ［右键单击上一行首，选择更新域键入公司名称的全称］ ［右键单击上一行首，选择更新域键入公司名称的简称］ 上海凯利泰医疗科技股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 ...

Financial Performance - In 2023, the company achieved operating revenue of RMB 956.26 million, a decrease of 17.99% compared to the previous year[6]. - The net profit attributable to shareholders was RMB 112.54 million, an increase of 628.78% year-on-year[6]. - The decline in revenue was primarily due to the implementation of the national volume-based procurement policy affecting the sales prices of orthopedic products[6]. - The company fully recognized goodwill impairment of RMB 197.99 million from the acquisition of Aideer in the previous year, contributing to the significant profit increase in 2023[6]. - The report indicates that the overall operating performance showed substantial changes compared to the same period last year[6]. - The company's operating revenue for 2023 was ¥956,259,537.45, a decrease of 17.99% compared to ¥1,166,042,082.06 in 2022[23]. - Net profit attributable to shareholders was ¥112,537,303.89, a significant increase of 628.78% from a loss of ¥21,282,494.18 in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥61,648,763.58, up 327.50% from a loss of ¥27,098,445.37 in 2022[23]. - Cash flow from operating activities was ¥274,260,691.58, representing a 15.84% increase from ¥236,756,963.51 in 2022[23]. - Basic and diluted earnings per share were both ¥0.1570, a 630.41% increase from a loss of ¥0.0296 in 2022[23]. - Total assets at the end of 2023 were ¥3,354,004,114.33, a decrease of 1.70% from ¥3,412,148,611.26 at the end of 2022[23]. - Net assets attributable to shareholders increased by 4.39% to ¥2,859,842,987.33 from ¥2,739,569,604.96 in 2022[23]. - The company reported a quarterly revenue of ¥294,401,832.83 in Q1 2023, which decreased to ¥213,839,891.49 in Q3 2023[26]. - The company experienced a net profit of ¥74,900,497.03 in Q1 2023, which turned into a loss of ¥16,629,549.62 in Q4 2023[26]. - In 2023, the company reported a total profit of 50,888,540.31, a significant increase from 5,815,951.19 in 2022, marking a year-over-year growth of approximately 775.5%[31]. - The company received government subsidies amounting to 23,359,830.49 in 2023, compared to 22,158,373.72 in 2022, reflecting a growth of about 5.4%[31]. Business Operations and Strategy - The company plans to continue monitoring the impact of procurement policies on its business operations and adjust strategies accordingly[7]. - The company is undergoing changes in accounting policies due to new regulations effective from January 1, 2022, impacting financial reporting[24]. - The company is committed to continuous development in minimally invasive orthopedic medical devices, covering multiple product lines including spinal and trauma products[35]. - The company is navigating regulatory challenges and opportunities presented by recent healthcare reforms, which are reshaping the competitive landscape in the orthopedic medical device sector[36]. - The company plans to enhance its product innovation in orthopedics, focusing on new materials and technologies, while also expanding its business lines to mitigate the negative impacts of procurement policies[42]. - The company is actively developing a diversified medical device distribution service platform to improve its market share and influence in the medical device sales sector[48]. - The company aims to implement a "one invoice system" sales model targeting large hospitals, in line with national medical reform policies[48]. - The company is focusing on innovation in orthopedic products and expanding its international market presence[62]. - The company is implementing cost control measures to enhance profitability, including reducing labor costs and optimizing production processes[62]. - The company is expanding its product specifications to meet market demands, enhancing competitiveness in the orthopedic and neurosurgical product lines[92]. - The company plans to pursue capital expansion strategies through acquisitions and investments in related medical device companies, particularly in the minimally invasive orthopedic field[135]. - The company will enhance its multi-brand strategy by integrating existing sales channels and strengthening collaboration across product lines, aiming to establish a diverse sales network targeting hospitals[136]. - The company plans to accelerate the internationalization strategy, focusing on the PKP/PVP and Elliquence product lines, with dedicated management roles for foreign trade development in various countries[137]. Market and Industry Trends - The orthopedic implant medical device industry is experiencing rapid growth, with domestic companies benefiting from market expansion and import substitution[36]. - The average price reduction in orthopedic trauma medical consumables during centralized procurement reached 88.65%, significantly impacting industry expectations[37]. - The average price drop for selected orthopedic spinal consumables in centralized procurement was 84%, effective from January 2023[39]. - The national centralized procurement for high-value medical consumables, including artificial crystals and sports medicine supplies, resulted in an average price drop of 74% for sports medicine consumables[40]. - The implementation of bulk procurement policies in the orthopedic consumables sector is expected to significantly reduce patient financial burdens and standardize medical practices, leading to the gradual elimination of smaller, less innovative companies[41]. - The medical device industry is facing challenges due to policies aimed at controlling medical insurance costs, which may limit the growth of medical device expenses in healthcare institutions[130]. - The implementation of volume-based procurement policies is expected to increase pressure on pharmaceutical companies while also improving the quality and competitiveness of the medical industry[132]. - Increased competition in the orthopedic market is anticipated, necessitating timely product innovation to maintain profit margins[146]. Research and Development - R&D investment totaled 60.35 million yuan, a decrease of 8.30 million yuan or 12.09% year-on-year, with R&D expenditure accounting for 6.31% of current revenue, an increase of 0.42 percentage points[69]. - The company authorized 37 patents during the reporting period, including 5 invention patents, emphasizing its commitment to intellectual property management[69]. - The number of R&D personnel increased to 104 in 2023, a rise of 25.30% compared to 83 in 2022[93]. - The proportion of R&D personnel with master's degrees increased by 180.00%, from 5 in 2022 to 14 in 2023[93]. - The company is focusing on optimizing its surgical instrument packages based on clinical feedback, which is expected to improve operational efficiency[93]. - The company aims to strengthen its research and development capabilities, focusing on minimally invasive orthopedic surgical products to maintain a competitive edge in the market[134]. Acquisitions and Investments - The company has successfully integrated its product lines and sales channels following the acquisition of Aideer, optimizing its offerings in orthopedic implants and surgical instruments[46]. - The acquisition of Elliquence, LLC has allowed the company to expand into new business areas, particularly in surgical energy platforms and high-value consumables, enhancing its market presence[47]. - The company acquired a 56% stake in Jienuo Medical, enhancing its market competitiveness and operational efficiency in the medical sterilization service sector[50]. - The company completed the acquisition of 100% equity in Elliquence, LLC for approximately $77,152,000 (about ¥49,500 million) as part of its internationalization strategy[1]. - The company completed the acquisition of 100% equity in Jiangsu Aidi Medical Technology Co., Ltd., enhancing its market position[120]. - The registered capital of Jiangsu Aidi was increased from 60 million yuan to 110 million yuan, reflecting the company's commitment to growth[121]. - The company invested 15 million yuan in the Shanghai Hongsheng Houde Private Equity Investment Fund and 10 million yuan in Dongzhi Medical, among other investments, to enhance its industry presence[72]. Governance and Compliance - The financial report was confirmed to be accurate and complete by the board of directors and management, with no significant discrepancies noted[4]. - The company has established independent financial, operational, and personnel systems, ensuring no interference from existing shareholders[183]. - The company has implemented information disclosure management systems to ensure transparency and timely communication with stakeholders[170]. - The company respects and protects the rights of all stakeholders, promoting sustainable and healthy development[171]. - The company has conducted 1 annual and 1 extraordinary shareholders' meeting during the reporting period, ensuring compliance with legal requirements[163]. - The company maintains strict compliance with the "Investor Relations Management System" to ensure effective communication with investors[172]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[168]. Future Outlook - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[190]. - The company is investing 368.4 million in research and development for new technologies and products in the upcoming year[191]. - Market expansion efforts are focused on increasing presence in Southeast Asia, with a target of capturing an additional 10% market share by 2025[192]. - New product lines are expected to launch in Q3 2024, which are anticipated to contribute an additional 5% to overall revenue[194]. - The company has set a goal to reduce operational costs by 10% through efficiency improvements and technology integration[197]. - The company aims to enhance customer engagement through digital platforms, expecting a 30% increase in online interactions[200]. - Future guidance indicates a focus on sustainability initiatives, with a commitment to reduce carbon emissions by 20% over the next five years[200].